Adam J. Townsend, Chief Commercial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 5,000 shares at $74.05 ($370K) on 2023-04-03, disclosed to the SEC on 2023-04-05.
Scheduled sale ($370k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2025-01-21 | $132K | — | Filing → |
| APLS | SELL | 2025-01-14 | $154K | — | Filing → |
| APLS | SELL | 2024-02-13 | $156K | — | Filing → |